Germany prioritizes medical biotechnology with new initiatives

The new round of funding by Germany¹s Ministry of Education and Research will provide EUR 40 million for biotechnology research.

At the same time, the Health ­ Made in Germany initiative has been set up to turn Germany into a business hub for the international health care industry. With these new initiatives, Germany is consolidating its position as Europe¹s top medical biotechnology location.

³We are hosting a breakfast seminar on September 18 in Boston to bring together important players from the German and American biotechnology sectors. One of Germany¹s top clusters, BioM Munich and Massachusetts association MassBio will have a chance to highlight bilateral ties. This meeting will be a great start to this year¹s BioPharm America 2012,happening from September 19-21 in Boston,² stated Sandra Buetow, pharmaceutical industry expert for Germany Trade & Invest in Berlin.

Germany features over 500 dedicated biotechnology companies. Nearly half of these companies develop new drugs or diagnostic methods in the areas of human and animal medicine, making this one of the most important applications of biotechnology. The United States is the top investor in Germany, according to Germany Trade & Invest statistics. At the same time, the USA is an essential market for German exports.

Health ­Made in Germany is an initiative to create win-win situations for global partners and German health care companies. Supported by the Federal Ministry of Economics and Technology and carried out by Germany Trade & Invest, the initiative allows companies, federal clusters, and professional associations to benefit from business opportunities in the health care field.
More in Home